bioAffinity Technologies, Inc. Warrant financials
$0.2600−18.75%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.6M | $1.4M | $1.3M | $1.9M | $2.2M | $2.4M | $2.4M | $2.4M | $2.2M | $298.5K |
| Gross profit | $1.5M | $1.4M | $692.7K | $503.9K | $1.3M | $1.9M | $645.4K | $910.2K | $989.9K | $833.0K | $548.5K | $223.8K |
| Gross margin | 100.0% | 100.0% | 43.5% | 34.8% | 100.0% | 100.0% | 29.2% | 38.7% | 41.3% | 34.6% | 24.8% | 75.0% |
| Operating income | -$3.3M | -$3.6M | -$3.1M | -$2.3M | -$2.5M | -$2.6M | -$2.9M | -$2.0M | -$2.1M | -$1.9M | -$2.3M | -$2.3M |
| Net income | -$3.4M | -$3.6M | -$3.1M | -$5.1M | -$4.1M | -$2.7M | -$3.0M | -$2.0M | -$2.1M | -$2.0M | -$2.4M | -$2.3M |
| Net margin | −222.8% | −268.6% | −197.0% | −349.3% | −319.9% | −143.5% | −134.4% | −85.1% | −88.0% | −81.5% | −107.2% | −767.5% |
| Diluted EPS | $-9.60 | $-12.15 | — | $-71.10 | $-76.05 | $-2.40 | $-49.85 | $-72.60 | $-85.50 | $-90.00 | $-114.35 | $-117.00 |
| EBITDA | -$3.3M | -$3.5M | -$3.0M | -$2.2M | -$2.4M | -$2.5M | -$2.9M | -$1.8M | -$1.9M | -$1.8M | -$2.2M | -$2.2M |
| Operating cash flow | -$3.2M | -$3.2M | -$2.6M | -$2.5M | -$2.6M | -$1.6M | -$1.7M | -$1.7M | -$1.5M | -$2.3M | -$1.6M | -$1.5M |
| Free cash flow | -$3.3M | -$3.2M | -$2.6M | -$2.5M | -$2.7M | -$1.7M | -$1.7M | -$1.7M | -$1.6M | -$2.4M | -$1.6M | -$1.5M |
| Diluted shares | 0.3M | 0.3M | — | 0.1M | 0.1M | 1.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.4M | $3.1M | $6.4M | $7.7M | $802.8K | $444.7K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $634.1K | $695.1K | $818.7K | $305.8K | $262.7K | $892.4K |
| Total assets | $7.6M | $7.9M | $11.0M | $11.5M | $4.8M | $5.5M |
| Total liabilities | $3.9M | $4.3M | $3.7M | $2.6M | $6.9M | $4.1M |
| Shareholders' equity | $3.8M | $3.7M | $7.3M | $8.9M | -$2.1M | $1.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology